Aeterna Zentaris (NASDAQ:AEZS) Coverage Initiated at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Price Performance

Aeterna Zentaris stock opened at $8.03 on Wednesday. The stock’s 50 day moving average price is $8.04 and its 200 day moving average price is $7.63. The company has a market cap of $9.72 million, a PE ratio of -0.59 and a beta of 1.60. Aeterna Zentaris has a 1-year low of $5.44 and a 1-year high of $13.20.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($4.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.88) by ($0.76). Aeterna Zentaris had a negative return on equity of 63.20% and a negative net margin of 368.01%. The firm had revenue of $0.12 million during the quarter.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.